PharVision Advisers’s CTO Realty Growth CTO Stock Holding History

PharVision Advisers’s Portfolio CTO Stock Details CTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,818	Closed	-$218K	–	236
2025 Q4	$218K	Buy	+11,818	New	+$202K	0.11%	487

Other funds holding CTO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRES

Heitman Real Estate Securities Chicago, Illinois $1.56B AUM 21.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cutler Capital Management Worcester, Massachusetts $385M AUM 19.11% 1-Year Est. Return

GWI

Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

PharVision Advisers's CTO Position: Q1 2026 in Review

PharVision Advisers sold out of CTO Realty Growth (CTO) in Q1 2026, closing a stake of 11,818 shares — an estimated $218K sold.

PharVision Advisers first reported a position in CTO in Q4 2025 and held it in 1 quarter. The position peaked at $218K in Q4 2025. 198 funds tracked by Wall St. Rank hold CTO as of Q1 2026.

PharVision Advisers reported no remaining CTO Realty Growth position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 11,818 CTO Realty Growth shares in Q1 2026, an estimated $218K.
PharVision Advisers first reported a position in CTO Realty Growth in Q4 2025 and held it in 1 quarter.
PharVision Advisers's CTO Realty Growth position peaked at $218K in Q4 2025.
198 funds tracked by Wall St. Rank held CTO Realty Growth as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.